Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer

Prediction of outcome in patients with metastatic breast cancer remains problematical. The present study evaluated the value of an inflammation-based score (Glasgow Prognostic Score, GPS) in patients with metastatic breast cancer. The GPS was constructed as follows: patients with both an elevated C-...

Descripción completa

Detalles Bibliográficos
Autores principales: Murri, A M Al, Bartlett, J M S, Canney, P A, Doughty, J C, Wilson, C, McMillan, D C
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361117/
https://www.ncbi.nlm.nih.gov/pubmed/16404432
http://dx.doi.org/10.1038/sj.bjc.6602922
_version_ 1782153143489921024
author Murri, A M Al
Bartlett, J M S
Canney, P A
Doughty, J C
Wilson, C
McMillan, D C
author_facet Murri, A M Al
Bartlett, J M S
Canney, P A
Doughty, J C
Wilson, C
McMillan, D C
author_sort Murri, A M Al
collection PubMed
description Prediction of outcome in patients with metastatic breast cancer remains problematical. The present study evaluated the value of an inflammation-based score (Glasgow Prognostic Score, GPS) in patients with metastatic breast cancer. The GPS was constructed as follows: patients with both an elevated C-reactive protein (>10 mg l(−1)) and hypoalbuminaemia (<35 g l(−1)) were allocated a score of 2. Patients in whom only one or none of these biochemical abnormalities was present were allocated a score of 1 or 0, respectively. In total, 96 patients were studied. During follow-up 51 patients died of their cancer. On multivariate analysis of the GPS and treatment received, only the GPS (HR 2.26, 95% CI 1.45–3.52, P<0.001) remained significantly associated with cancer-specific survival. The presence of a systemic inflammatory response (the GPS) appears to be a useful indicator of poor outcome independent of treatment in patients with metastatic breast cancer.
format Text
id pubmed-2361117
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23611172009-09-10 Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer Murri, A M Al Bartlett, J M S Canney, P A Doughty, J C Wilson, C McMillan, D C Br J Cancer Clinical Study Prediction of outcome in patients with metastatic breast cancer remains problematical. The present study evaluated the value of an inflammation-based score (Glasgow Prognostic Score, GPS) in patients with metastatic breast cancer. The GPS was constructed as follows: patients with both an elevated C-reactive protein (>10 mg l(−1)) and hypoalbuminaemia (<35 g l(−1)) were allocated a score of 2. Patients in whom only one or none of these biochemical abnormalities was present were allocated a score of 1 or 0, respectively. In total, 96 patients were studied. During follow-up 51 patients died of their cancer. On multivariate analysis of the GPS and treatment received, only the GPS (HR 2.26, 95% CI 1.45–3.52, P<0.001) remained significantly associated with cancer-specific survival. The presence of a systemic inflammatory response (the GPS) appears to be a useful indicator of poor outcome independent of treatment in patients with metastatic breast cancer. Nature Publishing Group 2006-01-30 2006-01-10 /pmc/articles/PMC2361117/ /pubmed/16404432 http://dx.doi.org/10.1038/sj.bjc.6602922 Text en Copyright © 2006 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Clinical Study
Murri, A M Al
Bartlett, J M S
Canney, P A
Doughty, J C
Wilson, C
McMillan, D C
Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer
title Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer
title_full Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer
title_fullStr Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer
title_full_unstemmed Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer
title_short Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer
title_sort evaluation of an inflammation-based prognostic score (gps) in patients with metastatic breast cancer
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361117/
https://www.ncbi.nlm.nih.gov/pubmed/16404432
http://dx.doi.org/10.1038/sj.bjc.6602922
work_keys_str_mv AT murriamal evaluationofaninflammationbasedprognosticscoregpsinpatientswithmetastaticbreastcancer
AT bartlettjms evaluationofaninflammationbasedprognosticscoregpsinpatientswithmetastaticbreastcancer
AT canneypa evaluationofaninflammationbasedprognosticscoregpsinpatientswithmetastaticbreastcancer
AT doughtyjc evaluationofaninflammationbasedprognosticscoregpsinpatientswithmetastaticbreastcancer
AT wilsonc evaluationofaninflammationbasedprognosticscoregpsinpatientswithmetastaticbreastcancer
AT mcmillandc evaluationofaninflammationbasedprognosticscoregpsinpatientswithmetastaticbreastcancer

Ejemplares similares